Copper for Cardiovascular Disease
Copper is an essential mineral, but there is no good evidence that taking copper supplements prevents cardiovascular disease. In fact, observational studies consistently link higher blood copper to greater heart risk, so this earns only a weak (C) grade.
Why this grade7-layer evidence engine
The grade is held to weak (C) because the human data are almost entirely observational and, critically, point the opposite way from a benefit. A large meta-analysis of 16 studies and 41,322 people (PMID 37441705) found that people with the highest serum copper had higher cardiovascular mortality (pooled OR 1.60), myocardial infarction (1.31), and stroke (1.49). Long prospective cohorts agree: the Finnish KIHD study (PMID 35083177) tied higher copper to coronary heart disease (HR 1.32) but not venous clots, and an NHANES cohort (PMID 37915007) reported higher cardiovascular death, though its extreme estimate (HR 7.06) had a very wide confidence interval.
Importantly, these associations probably reflect inflammation rather than copper causing disease. Copper travels on ceruloplasmin, an acute-phase protein, and a systematic review (PMID 33096845) found that adjusting for the inflammatory marker hsCRP cut the excess risk by about a third. A heart-failure meta-analysis (PMID 31826374) likely shows reverse causation (illness raising copper), and a PREDIMED analysis (PMID 37580236) found harm only in men. The only signal that low copper harms the heart comes from a rare genetic disease, Menkes (PMID 22134099), and a mouse aneurysm model (PMID 31554420) -- not from ordinary adults.
Regulators and clinics reinforce the cautious read. The NIH Office of Dietary Supplements describes copper only as an essential enzyme cofactor, with no cardiovascular claim, and the UK NHS says a balanced diet supplies all the copper you need. The FDA and EFSA recognise copper purely as a nutrient (Daily Value 0.9 mg) and have tightened, not loosened, safe upper limits. No randomized trial shows copper supplements reduce heart events, so supplementing for cardiovascular protection is unsupported and potentially counterproductive.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.477
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status